NCT03747731

Brief Summary

The present study aims to evaluate, with non-invasive methods, the relationships existing between PEEP and renal perfusion in patients undergoing surgery and requiring ventilatory support and monitoring in intensive care. Renal perfusion will be assessed at baseline (PEEP 0), subsequently ,at the application of progressive increases of PEEP. At the end of the measurements, the implications of the use of PEEP on the renal vascular system will be analyzed.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
109

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 18, 2018

Completed
1 day until next milestone

Study Start

First participant enrolled

November 19, 2018

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 20, 2018

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 19, 2019

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 19, 2019

Completed
Last Updated

February 1, 2019

Status Verified

November 1, 2018

Enrollment Period

6 months

First QC Date

November 18, 2018

Last Update Submit

January 31, 2019

Conditions

Keywords

Renal blood perfusionMechanical ventilation

Outcome Measures

Primary Outcomes (1)

  • Association between IR and PEEP

    Resistive index will be measured in both kidney and recorded using multifrequency convex probe.The association between positive end expiratory pressure and resistive index will be analyzed as the primary outcome.

    Change from baseline to 60 minutes

Secondary Outcomes (1)

  • Association between PEEP and Hemodynamics Paramenters

    Change from baseline to 60 minutes

Other Outcomes (1)

  • Association between IR and Respiratory exchanges

    Change from baseline to 60 minutes

Study Arms (1)

Resistive Index and Peep Titration

Enrolled patients will receive a sequential, step-wise increase in PEEP from 0 cmH2O to 12 cmH2O. The inter-lobar arterioles will be sampled at each PEEP increment and the IR will be measured as the average of three values recorded at the upper and lower pole and at the mesorenes in each kidney. Gas exchanges, HR, systolic, diastolic and mean PA, Pmax, P1 and P2 airway, total resistance and ohmic resistance and static respiratory compliance indexed for body weight (RRSmaxI, RRSminI, CrsI) will be measured at each Peep Level. The physiologic measurements will be obtained at regular intervals (within 15 minutes at each PEEP level) throughout the PEEP titration period.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing surgery and with the need for ventilatory support for the intensive care unit

You may qualify if:

  • Years and older
  • Receiving mechanical ventilation, invasive blood pressure monitoring and an urinary catheter to monitor diuresis
  • Need for postoperative monitoring in intensive care
  • Written informed consent;

You may not qualify if:

  • Acute kidney injury defined according to KDIGO guidelines;
  • Pre-existing chronic renal disease;
  • Heart failure;
  • ARDS;
  • Sepsis and Septic Shock;
  • Hemodynamic instability with the need for vasoactive support;
  • Chronic or occasional therapy with drugs that could modify the renal blood flow and that can not be suspended two days before the study (Vasoactive agents, Ace-inhibitors, Beta-blockers, NSAIDs, Sartans and Diuretics therapy);
  • Presumed or established state of pregnancy;
  • Refusal of informed consent;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

San Bortolo Hospital

Vicenza, 36100, Italy

RECRUITING

Study Officials

  • Silvia De Rosa, MD

    Ospedale San Bortolo di Vicenza

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Silvia De Rosa, MD

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Doctor

Study Record Dates

First Submitted

November 18, 2018

First Posted

November 20, 2018

Study Start

November 19, 2018

Primary Completion

May 19, 2019

Study Completion

November 19, 2019

Last Updated

February 1, 2019

Record last verified: 2018-11

Data Sharing

IPD Sharing
Will not share

Locations